IGM Biosciences, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2024-05-29: Study NCT06524687; Company role Lead sponsor; Phase Phase 1; Status Terminated.
- 2023-08-29: Study NCT05908396; Company role Lead sponsor; Phase Phase 1; Status Terminated.
- 2023-08-15: Study NCT06041568; Company role Lead sponsor; Phase Phase 1; Status Terminated.
- 2023-03-15: Study NCT06087406; Company role Lead sponsor; Phase Phase 1; Status Terminated.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2024-05-29 | NCT06524687 A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies | Lead sponsor | Phase 1 | Terminated | Idiopathic Inflammatory Myopathies; Inflammatory Myopathies | 2 | 2025-01-21 |
| 2023-08-29 | NCT05908396 Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma | Lead sponsor | Phase 1 | Terminated | Multiple Myeloma | 4 | 2024-02-16 |
| 2023-08-15 | NCT06041568 A Study of Imvotamab in Severe Systemic Lupus Erythematosus | Lead sponsor | Phase 1 | Terminated | Systemic Lupus Erythematosus; Lupus Erythematosus | 17 | 2025-01-27 |
| 2023-03-15 | NCT06087406 A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis | Lead sponsor | Phase 1 | Terminated | Rheumatoid Arthritis; Arthritis, Rheumatoid; Arthritis | 33 | 2025-02-10 |
| 2023-01-10 | NCT05702424 Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer | Lead sponsor | Phase 1 | Completed | Solid Tumor | 14 | 2024-05-31 |
| 2022-01-20 | NCT05184218 Evaluation of IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19 | Lead sponsor | Phase 1 | Terminated | Healthy Volunteers; COVID-19 | 26 | 2022-07-04 |
| 2021-12-07 | NCT05160402 Evaluation of IGM-6268 in Healthy Volunteers | Lead sponsor | Phase 1 | Terminated | Healthy Volunteers | 54 | 2022-08-18 |
| 2020-09-23 | NCT04553692 Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers | Lead sponsor | Phase 1 | Terminated | Solid Tumor; Colorectal Cancer; Non Hodgkin Lymphoma; Sarcoma; Chondrosarcoma; Small Lymphocytic Lymphoma; Chronic Lymphocytic Leukemia; Acute Myeloid Leukemia | 272 | 2025-01-20 |
| 2019-09-30 | NCT04082936 A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma | Lead sponsor | Phase 1, Phase 2 | Terminated | Non-Hodgkin Lymphoma; Follicular Lymphoma; DLBCL; Mantle Cell Lymphoma; Marginal Zone Lymphoma | 97 | 2024-02-22 |
| NCT06331832 Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL | Lead sponsor | Expanded_access | No longer available | Relapsed/Refractory Non-Hodgkin Lymphomas |